---
layout: post
title: "Half life of PrP and its mRNA"
author: ericminikel
date: 2013-04-08 13:28:41
---
<p><strong>update 2013-07-31: here&#8217;s a quick summary table of what&#8217;s available in the published literature:</strong></p>
<p><strong>Half lives of PrP mRNA, PrP<sup>C</sup> and PrP<sup>Sc</sup></strong></p>
<p><table style="width:100%; " class="easy-table easy-table-default " border="0">
<thead>
<tr><th>molecule</th>
<th>N2a cells</th>
<th>in vivo</th>
</tr>
</thead>
<tbody>
<tr><td>PrP mRNA</td>
<td>7h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8095862">Pfeifer 1993</a>]</td>
<td></td>
</tr>

<tr><td>PrP<sup>C</sup></td>
<td>5.2h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/1968466/">Borcheldt 1990</a> (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2116048/pdf/jc1103743.pdf">ft</a>)]<br/>3-6h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/2562814">Caughey 1989</a> (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC247670/pdf/jvirol00068-0193.pdf">ft</a>)]</td>
<td>18h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16186247">Safar 2005</a> (<a href="http://vir.sgmjournals.org/content/86/10/2913.long">ft</a>)]</td>
</tr>

<tr><td>sPrP<sup>Sc</sup></td>
<td></td>
<td>36h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16186247">Safar 2005</a> (<a href="http://vir.sgmjournals.org/content/86/10/2913.long">ft</a>)]</td>
</tr>

<tr><td>rPrP<sup>Sc</sup></td>
<td>30h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11507642">Peretz 2001</a> (<a href="http://www.nature.com/nature/journal/v412/n6848/full/412739a0.html">ft</a>)]</td>
<td>36h [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16186247">Safar 2005</a> (<a href="http://vir.sgmjournals.org/content/86/10/2913.long">ft</a>)]</td>
</tr>
</tbody></table></p>
<p><em>rPrP<sup>Sc</sup> = proteinase K-resistant PrP<sup>Sc</sup>, aka PrP-res.</em><br/>
<em>sPrP<sup>Sc</sup> = proteinase K-sensitive PrP<sup>Sc</sup>.</em></p>
<p><strong>end update. original post follows.</strong></p>
<hr/>
<p>A few days ago <a href="/2013/04/04/tacrolimus-astemizole-and-a-new-screening-approach-for-drugs-that-reduce-prp/#lasmezasqa">I commented</a> that it was unclear what timeline of drug treatment would be needed to observe an effect of compounds that inhibit PrP transcription.  I did some more digging and found that there is a bit of literature on this.</p>
<p>First, to clear up <a href="/2013/04/08/the-case-for-depleting-prp-as-a-therapeutic-strategy-against-prion-diseases/#knockdownlevelquestion">an earlier confusion</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/16186247">Safar 2005</a> (<a href="http://vir.sgmjournals.org/content/86/10/2913.long">ft</a>) states that PrP expression in Tet-off mice declined to ~40% of initial levels after 1 day of doxycycline and to ~5% after one week.  But note that &#8216;initial levels&#8217; in this mouse model are about double the normal expression level for wild-type mice due to the strong Tet promoter [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22873/">Tremblay 1998</a>], so this 5% corresponds to something more like 10% of wild-type levels.  To be quite precise, Safar&#8217;s homozygous Tg(tTA : PrP<sup>+/+</sup>)3 mice expressed PrP at 4 times wild-type levels, but these experiments were done on heterozygous Tg(tTA : PrP<sup>+/0</sup>)3 mice, and Safar states that:</p>
<blockquote><p>When Tg(tTA : PrP<sup>+/0</sup>)3 mice were given 2 mg doxycycline ml<sup>−1</sup> in the drinking water, PrP<sup>C</sup> expression decreased to 0·1-fold</p></blockquote>
<p>Thus confirming the figure of ~10% of wild-type levels.  See also <a href="http://jgv.sgmjournals.org/content/86/10/2913/T1.expansion.html">Table 1</a>.</p>
<p>Even at this level of expression, the mice <em>did </em>eventually succumb to prion disease, suggesting that the &#8216;critical threshold&#8217; of tolerable PrP<sup>Sc</sup> production, if there is one, is yet lower than 10% &#8211; a challenge for <a title="The case for depleting PrP as a therapeutic strategy against prion diseases" href="/2013/04/08/the-case-for-depleting-prp-as-a-therapeutic-strategy-against-prion-diseases/">the therapeutic strategy of depleting PrP</a>.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/16186247">Safar 2005</a> (<a href="http://vir.sgmjournals.org/content/86/10/2913.long">ft</a>) also quantifies the half-life of PrP and its mRNA.  PrP<sup>C</sup> is said to have a half-life of 18h in the mouse brain.  The longer half-life of PrP<sup>Sc</sup> (measured at 36h) means that once PrP production begins to decline following doxycycline administration, PrP<sup>Sc</sup> begins to account for a proportionally larger fraction of total PrP in the brain.</p>
<p>However, Safar notes that the half-life of PrP<sup>C</sup> in ScN2a cells &#8211; the RML prion-infected mouse neuroblastoma cell line most widely used in drug screens &#8211; is no more than 7h [<a href="http://jgv.sgmjournals.org/content/86/10/2913/T2.expansion.html">Table 2</a>], citing data from [Borcheldt &amp; Prusiner 1988, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC247670/">Caughey 1989</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/1968466/">Borcheldt 1990</a> (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2116048/pdf/jc1103743.pdf">ft</a>), <a href="http://www.ncbi.nlm.nih.gov/pubmed/11507642">Peretz 2001</a> (<a href="http://www.nature.com/nature/journal/v412/n6848/full/412739a0.html">ft</a>)].  PrP<sup>Sc</sup> takes longer, though, with a half-life of perhaps 30h in ScN2a cells [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11507642">Peretz 2001</a> (<a href="http://www.nature.com/nature/journal/v412/n6848/full/412739a0.html">ft</a>)], suggesting a longer timeline  may be needed to observe therapeutic effects in infected cultures.</p>
<p>As for PrP mRNA, Safar states that &#8220;PrP mRNA and PrP<sup>C</sup> have consistently short<em>t</em><sub>1/2</sub> values in ScN2a cells&#8221; and appears to cite [<a href="http://www.ncbi.nlm.nih.gov/pubmed/1968466/">Borcheldt 1990</a> (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2116048/pdf/jc1103743.pdf">ft</a>), <a href="http://www.ncbi.nlm.nih.gov/pubmed/15374100">Muller 1997</a>].  But in fact Borcheldt does not quantify mRNA, instead citing <a href="http://www.ncbi.nlm.nih.gov/pubmed/3923361">Chesebro 1985</a>, which was the original landmark study that used complementary RNA probes to discover PrP-encoding DNA in both infected and uninfected mice, an important piece of evidence for the prion hypothesis.  But Chesebro did not quantify mRNA half-life.  That leaves <a href="http://www.ncbi.nlm.nih.gov/pubmed/15374100">Muller 1997</a>, an old study in an obscure journal for which I cannot find full text &#8211; but the abstract certainly doesn&#8217;t say anything about mRNA half-life.  The <a href="http://www.ncbi.nlm.nih.gov/pubmed/16186247">Safar 2005</a> (<a href="http://vir.sgmjournals.org/content/86/10/2913.long">ft</a>) paper itself does not explicitly quantify PrP mRNA at any point, though since PrP expression is being shut off via a transcriptional mechanism, some information can be inferred from the data.  Looking at Safar&#8217;s data, on one hand, PrP<sup>C</sup> declined to 40% of original levels in just a day, suggesting a fast degradation of the mRNA (and the protein itself), but then it is hard to explain exactly why the peak inhibition was not attained until after 7 days.  And these data concern the mouse brain, so they can&#8217;t tell us much about the half life of PrP mRNA in N2a cells.</p>
<p>To summarize:</p>
<ul>
<li>PrP Tet-off mice with PrP expression reduced to 10% of wild-type levels still succumb to scrapie, suggesting that PrP depletion strategies will need to do better than this in order to reverse symptomatic disease.</li>
<li>Rapid reduction in PrP levels in Tet-off mice following doxycycline administration may suggest a short half-life of PrP mRNA in the mouse brain.</li>
<li><del>I cannot find any studies which have explicitly quantified the half-life of PrP mRNA in live animals or in cell cultures, including the N2a cells widely used in drug discovery screens.</del><strong> see below</strong></li>
</ul>
<p><strong>update 2013-04-09: </strong>@g dug up this old paper: [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8095862">Pfeifer 1993</a>] which quantified PrP mRNA half life at 7h in both N2a and ScN2a cells.</p>
